ADEM, or acute disseminated encephalomyelitis, is a rare inflammatory condition in which the immune system suddenly attacks the protective coating around nerve fibers in the brain and spinal cord. It most often strikes children between ages 5 and 8, with an incidence of about 0.4 per 100,000 children per year. ADEM typically follows a viral or bacterial infection and, in most cases, occurs just once before resolving.
How ADEM Affects the Brain
The nerve fibers in your brain and spinal cord are wrapped in a fatty insulation called myelin, which helps electrical signals travel quickly between cells. In ADEM, immune cells that normally fight infections become misdirected and cross the blood-brain barrier, where they attack myelin instead. This process, called demyelination, disrupts communication throughout the nervous system and causes widespread inflammation.
The damage follows a distinctive pattern, clustering around small veins in the brain. This “perivenous” demyelination is considered ADEM’s pathological signature and helps distinguish it from other conditions. The inflammation can also trigger microscopic bleeding, activate immune cells in the brain’s outer layers, and produce the confusion and altered consciousness that set ADEM apart from other demyelinating diseases like multiple sclerosis.
Common Triggers
Most cases of ADEM begin about 7 to 14 days after an infection. The leading theory is molecular mimicry: proteins on the surface of certain viruses or bacteria resemble myelin proteins closely enough that the immune system, primed to fight the infection, accidentally targets the nervous system as well. Reported triggers include measles, mumps, rubella, chickenpox, influenza, and hepatitis A, though many common respiratory and gastrointestinal infections can precede ADEM.
Vaccination has occasionally been linked to ADEM in case reports, but large-scale studies have not confirmed a causal connection for routinely recommended vaccines. One study using the Vaccine Safety Datalink found a possible association with the Tdap vaccine, estimated at no more than 1.16 excess cases per million doses. For other vaccines, the evidence does not go beyond coincidental timing.
Symptoms and Timeline
ADEM often begins with nonspecific symptoms that look like a returning illness: fever, headache, nausea, vomiting, and fatigue. Within hours to days, neurological symptoms appear. These vary depending on which parts of the brain and spinal cord are inflamed, but they commonly include:
- Confusion or altered consciousness
- Numbness or tingling in the arms and legs
- Muscle weakness or difficulty walking
- Vision loss (from inflammation of the optic nerve)
- Difficulty swallowing
- Seizures
The encephalopathy, a noticeable change in mental status ranging from irritability and drowsiness to deep confusion, is a hallmark feature. Children may seem disoriented or unusually sleepy in ways that go well beyond normal illness fatigue. This altered awareness is one of the key features doctors look for when separating ADEM from other neurological conditions.
How ADEM Is Diagnosed
There is no single test for ADEM. Diagnosis relies on the combination of clinical presentation, MRI findings, and sometimes a spinal tap. On MRI, ADEM typically produces large, poorly defined, bright lesions scattered across the brain. These lesions often appear in the deep white matter, brainstem, and sometimes the basal ganglia or thalamus. Involvement of the basal ganglia or the brain’s outer cortex, while uncommon, is seen almost exclusively in ADEM rather than MS. Critically, the MRI should not show “black holes,” which are dark spots on certain imaging sequences that indicate older, previously damaged tissue. Their absence suggests that all the damage is fresh, consistent with a single inflammatory event.
A spinal tap can provide supporting evidence but results vary widely. About 20% of patients have completely normal spinal fluid. In the rest, doctors may find elevated white blood cells and protein levels, signs of an active inflammatory response inside the central nervous system.
The Role of MOG Antibodies
A blood test for antibodies against myelin oligodendrocyte glycoprotein (MOG) has become an important part of the workup. About 57% of children with ADEM test positive for these antibodies. Testing positive does not change the initial treatment, but it helps predict what happens next. Children whose MOG antibodies disappear over time have a lower risk of future episodes. Those who remain positive are more likely to relapse. Current recommendations suggest retesting every six months for up to two years to track whether antibody levels are declining.
How ADEM Differs From Multiple Sclerosis
ADEM and MS both involve immune attacks on myelin, so distinguishing them early matters for treatment and long-term planning. Several features help tell them apart. ADEM tends to affect younger children, peaks between ages 5 and 8, and slightly favors boys. MS in children typically presents at an older age and is more common in girls.
On MRI, MS lesions tend to be smaller, sharply defined, and concentrated around the brain’s ventricles, particularly in perpendicular streaks along the corpus callosum. ADEM lesions are larger, hazier, and more diffusely spread. The presence of basal ganglia or thalamus lesions points toward ADEM, while black holes and more than nine bright spots on T2-weighted imaging raise suspicion for MS. Certain markers found in spinal fluid, called oligoclonal bands, are strongly associated with MS. A combination of age, sex, MRI pattern, and spinal fluid results allows doctors to reliably distinguish the two conditions at the first episode in most cases.
Treatment
The standard first-line treatment is high-dose intravenous corticosteroids, typically given over three to five days. The goal is to rapidly suppress the immune attack and reduce brain swelling. After the IV course, doctors often prescribe an oral steroid taper lasting four to six weeks to prevent rebound inflammation.
Most children respond well to steroids alone. In severe cases, or when steroids do not produce improvement, second-line options include intravenous immunoglobulin (a concentrated dose of antibodies from donated blood) or plasma exchange, a procedure that filters harmful antibodies out of the blood. For the most resistant cases, stronger immune-suppressing medications may be used.
Children who are later found to have relapsing disease associated with persistent MOG antibodies often require longer-term immune therapy, sometimes for two or more years, followed by careful monitoring after treatment is stopped.
Recovery and Long-Term Outlook
The majority of children with ADEM recover fully. Published data suggest that 56% to 94% of patients achieve complete clinical recovery, depending on how recovery is measured. In one study of 65 children, about 62% were judged fully recovered, while the remaining 38% had some lasting effects.
When residual problems do occur, they tend to be subtle. Up to half of ADEM patients show mild cognitive difficulties on detailed neuropsychological testing, even when they appear fully recovered in daily life. Moderate to severe cognitive deficits are less common, affecting up to 18% of patients. The most frequent physical aftereffects are mild coordination problems or weakness on one side of the body. Psychosocial issues, including anxiety and attention difficulties, have been reported in 20% to 60% of patients in longer-term follow-up studies.
About 25% of children experience a second demyelinating episode. In roughly half of those cases, the new episode meets criteria for multiphasic ADEM, defined as a second ADEM attack occurring at least three months after the first, with either a return of previous symptoms or entirely new neurological signs and MRI findings. The remaining relapses may ultimately be reclassified as MS or MOG antibody-associated disease, which is why ongoing monitoring after an initial ADEM diagnosis is important.